Early results show benefit of remdesivir for COVID-19
At a Glance
- Early results showed that remdesivir benefited hospitalized patients with severe COVID-19 who required supplemental oxygen.
- While the findings support remdesivir as a standard therapy for such patients, they suggest more research is needed to improve outcomes for people with COVID-19.
Coronaviruses are a large family of viruses that usually cause mild to moderate upper-respiratory tract illnesses like the common cold. SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), is the third novel coronavirus to emerge over the past two decades. Since first appearing in China, COVID-19 has become an ongoing global pandemic. Infections can cause mild to extremely severe respiratory illness. Symptoms commonly include fever, cough, and shortness of breath.
By looking at studies on the previous two coronavirus outbreaks, which caused severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), researchers quickly identified potential treatments that might help reduce the severity of COVID-19. Remdesivir is one such investigational broad-spectrum antiviral treatment. It was previously tested in humans with Ebola virus disease and has shown promise in animal models for treating MERS and SARS.
To test whether remdesivir could help treat patients with COVID-19, a team of researchers carried out a randomized, controlled clinical trial called the Adaptive COVID-19 Treatment Trial (ACTT)…… Read More: